Search results
ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory...
Morningstar· 4 days agoPfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (elranatamab-bcmm) in patients with heavily ...
Former Pfizer Worker’s 401(k) Account Won’t Be Given to Ex-Wife
Bloomberg Law· 3 days agoemployee can’t access his 401(k) account to satisfy a $75,000 judgment against him in a defamation lawsuit, a Pennsylvania federal judge said. Judge Juan R. Sánchez rejected her request with ...
Pfizer's gene-therapy trial failure boosts Sarepta's stock
Morningstar· 5 days agoShares of Sarepta Therapeutics Inc. (SRPT) gained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a late-stage trial. Pfizer Inc. said ...
Pfizer’s gene therapy for a muscle-wasting disorder misses main goal of late-stage study
WSAU Wausau· 5 days ago(Reuters) - Pfizer said on Wednesday its experimental gene therapy for a type of muscle-wasting...
US FDA approves Merck's pneumococcal vaccine for adults
Reuters via Yahoo News· 4 hours agoThe disease can lead to infections in several parts of the body including the lungs, where they can...
Moderna stock is lone omen of bird flu pandemic
Reuters· 7 hours agoThe recent rise of Moderna’s stock tells a grim tale. The $56 billion company which pioneered a Covid vaccine has seen its market value rise 40% since...
Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine
Zacks via Yahoo Finance· 10 hours agoNovavax (NVAX) seeks FDA???s approval to update its COVID-19 vaccine for the 2024-2025 fall season...
Pfizer's Duchenne Muscular Dystrophy Treatment Misses Endpoints
Morningstar· 5 days agoPfizer's gene therapy being developed to treat Duchenne muscular dystrophy missed its primary endpoint in a late-stage trial. The pharmaceutical company said Wednesday the ...
Incubators, investment: How the Life Science Hub plans to bring biotech business to RI
The Providence Journal via Yahoo News· 17 hours agoA banker-turned-nonprofit leader, Steinberg retired from the Rhode Island Foundation last year and...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 5 days agoUsually, RSV causes coldlike symptoms in most people. But in newborns and older adults it can be...